Navigation Links
Scientific Results Presented At ECCMID Demonstrate Well-,Differentiated Profile of Basilea's Two Phase III Anti- infective,Compounds

hester, UK)

P1950 In vivo efficacy of the triazole BAL8557 against disseminated Candida albicans in mice assessed by survival and tissue burden in temporarily and persistently neutropenic mice treated with 1-7 doses of drug over a dose range of 20-80% of Emax. P.A. Warn, A. Parmar, A. Sharp, M. Heep, J. Spickermann, D.W. Denning (Manchester, UK; Basle, CH)

P1977 In vitro activity of isavuconazole (BAL4815/8557) compared with six other antifungal agents against 180 Cryptococcus neoformans meningitis isolates from the Netherlands. I. Curfs-Breuker, M. Illnait-Zaragozi, J. Mouton, B. Janssen, F. Hagen, L. Spanjaard, T. Boekhout, J. Meis (Nijmegen, NL; Havana, CU; Utrecht, Amsterdam, NL)

P1978 In vitro activity of isavuconazole (BAL4815) compared with seven other antifungal agents against 309 prospectively collected clinical Candida isolates from the Netherlands. I. Curfs-Breuker, J. Mouton, Y. Debets-Ossenkopp, H. Endtz, P. Verweij, J. Meis (Nijmegen, Amsterdam, Rotterdam, NL)

About Ceftobiprole

Ceftobiprole is an investigational anti-MRSA, broad-spectrum cephalosporin that has demonstrated positive results in two phase III trials in complicated skin and skin structure infections. Ceftobiprole has shown a low potential to select for resistance in vitro and exhibits activity against a wide spectrum of bacteria that cause many hospital and community-acquired infections including those due to resistant bacteria like methicillin-resistant Staphylococcus aureus (MRSA). Ceftobiprole has received fast track status from the FDA and is being developed through an exclusive worldwide collaboration between Basilea Pharmaceutica Ltd. and Cilag GmbH International, a Johnson & Johnson affiliate company.

About Isavuconazole

Isavuconazole has a potent and broad spectrum of activity against both yeasts and molds. This new triazole is developed as a water-soluble pro-drug to allow intravenous administration without contraindication in
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
2. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
3. VIVUS Announces Abstract Published at American Diabetes Association Scientific Sessions
4. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
5. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
6. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
7. Genaera to Present Preclinical Data on Trodusquemine for the Treatment of Obesity at the American Diabetes Association 67th Scientific Sessions
8. VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions
9. Inspire Announces Presentations at Two European Scientific Conferences
10. HepaLife Announces Scientific Presentation of PBS-1 Cell Line at International Influenza Meeting
11. Bentley Late Breaking Abstract Accepted for Poster Presentation at American Diabetes Association Scientific Sessions
Post Your Comments:
(Date:8/31/2015)... , Aug. 31, 2015 Pepperl+Fuchs, a ... acquired MACTek Corporation, a leading provider of HART ... strategy to further extend its integrated solutions offerings ...   "We are pleased to add ... portfolio," said Jim Bolin , Pepperl+Fuchs, executive ...
(Date:8/31/2015)... , Aug. 31, 2015  Daktari Diagnostics today announced ... the United States and Canada ... test. The deal, worth up to $8.5 million over the ... the clinical validation and regulatory approval of Daktari,s HCV test. ... a point-of-care instrument that can detect low levels of virus ...
(Date:8/31/2015)... , Aug. 31, 2015  On August 5, ... Oregon denied motions to dismiss ... GALE ) and certain of its directors. The ... a "pump and dump" scheme to artificially inflate Galena,s ... while the stock price was inflated, sold massive amounts ...
Breaking Medicine Technology:Daktari Enters Collaboration Agreement with Merck to Develop Test for Hepatitis C Virus 2Daktari Enters Collaboration Agreement with Merck to Develop Test for Hepatitis C Virus 3Galena Biopharma, Inc. Stock Alert: Schubert Firm Investigates Potential Breaches of Fiduciary Duty 2
... , , , SAN DIEGO, ... dedicated to developing life-saving medicines specifically designed to enhance ... through targeted oxygen delivery, today announced the initiation of ... efficacy of MP4OX treatment plus standard of care in ...
... Dec. 9 The U.S. Food and Drug Administration ... workshop series--an opportunity for biotechnology companies, pharmaceutical firms, academics ... applications for orphan status designation, under the guidance of ... The first workshop is planned for Feb. 25-26, 2010, ...
Cached Medicine Technology:Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock 2Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock 3FDA Launches Orphan Drug Workshop at KGI 2
(Date:8/31/2015)... ... 2015 , ... Since 1946, the doctors and staff at Clifton Dental Associates ... patient arrives at the office, the staff will make them feel welcome and comfortable. ... to create a complete dental treatment plan that is unique to each smile! ...
(Date:8/31/2015)... ... August 31, 2015 , ... How can healthcare meet ... down costs? , In a commentary for The American Journal of Managed ... of “clinical efficacy,” which would bind parties together in agreements to intervene at ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... Three Bakers ... visitors and retailers with even more relevant and easy-to-find information on their offering of ... “Our website has always been an important way for us to share information about ...
(Date:8/31/2015)... ... 2015 , ... Physicians’ Education Resource®, LLC (PER®) , ... Cancer Therapy for Tomorrow® meeting, is seeking abstract submissions for its 33rd ... The annual legacy meeting uses a variety of formats to educate all disciplines ...
(Date:8/31/2015)... ... August 31, 2015 , ... With baseball season in full swing, many ... will dominate the sports world. Fans desire nothing more than to see their favorite ... For children, especially those who are too young to really understand what all the ...
Breaking Medicine News(10 mins):Health News:NJ Top Dentists Presents, Clifton Dental Associates! 2Health News:How “Clinical Efficacy” Can Rein in Healthcare Costs 2Health News:How “Clinical Efficacy” Can Rein in Healthcare Costs 3Health News:Three Bakers Gluten Free Bakery Announces Launch of New Website 2Health News:Physicians’ Education Resource® Seeks Abstracts for the Upcoming Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® 2Health News:Physicians’ Education Resource® Seeks Abstracts for the Upcoming Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® 3Health News:Physicians’ Education Resource® Seeks Abstracts for the Upcoming Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® 4Health News:New Children's Baseball Series Offers Young Fans a Way to Celebrate the World Series 2
... -- Researchers and clinicians from the Indiana University School ... distinction between lab and clinic as they debut the ... care model they developed and extensively tested over the ... care is on two groups -- patients with cognitive ...
... International Journal of Emergency Medicine, a new quarterly publication ... research developments from around the world in emergency medicine. ... be available free of charge exclusively on Springers online ... issue will be published online in March 2008. , ...
... CHICAGO, Feb. 19 Viola Startzman, M.D. of,Wooster, Ohio ... M.D. Award for,Excellence in Volunteerism. Presented by the American ... domestic physicians for,commitment to volunteer medical care to those ... Foundation presents the award in association with the,Pfizer Medical ...
... M.D.,MDiv, of Memphis, Tenn., is a recipient of the ... Medical Association (AMA) Foundation, the,award is given to domestic ... Foundation presents the award in association with the,Pfizer Medical ... Monday, March 31st, at the 2008,Excellence in Medicine Awards ...
... Murli Manohar, M.D., Ph.D.,FACP, of Canton, Ohio, is a ... by the American Medical Association (AMA) Foundation, the,award is ... U.S. The AMA Foundation presents the award in association ... be presented on Monday, March 31st, at the 2008,Excellence ...
... Choices ( http://www.nhs.uk ),the digital ,front door, to ... help people assess their drinking behaviour and improve ... Based on NHS accredited information, the drinking assessment ... seconds whether they are drinking too much, and ...
Cached Medicine News:Health News:Merging discovery with therapy: Second generation memory care debuts 2Health News:Merging discovery with therapy: Second generation memory care debuts 3Health News:Springer to launch new journal in emergency medicine 2Health News:AMA Foundation Honors Wooster, Ohio Physician for Volunteerism 2Health News:AMA Foundation Honors Memphis, Tennessee Physician for Increasing Access to Health Care in the U.S. 2Health News:AMA Foundation Honors Canton, Ohio Physician for Increasing Access to Health Care in the U.S. 2
Introducer Sheath Designed for Vascular Access...
Used to introduce balloon, electrode, closed or non-tapered end and,other catheters....
... The Driver Stent design, ... surpasses the limitations of stainless ... makes possible thinner struts, for ... support. The Driver Coronary Stent ...
The TAXUS Express Paclitaxel-Eluting Coronary Stent System is indicated for improving luminal diameter for the treatment of de novo lesions = 28 mm in length in native coronary arteries = 2.5 to = 3....
Medicine Products: